Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

FibroGen to Report First Quarter 2024 Financial Results

GlobeNewswire 5 days ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

GlobeNewswire 10 days ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire April 2, 2024

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire March 26, 2024

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

GlobeNewswire March 11, 2024

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 26, 2024

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

GlobeNewswire February 26, 2024

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 20, 2024

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

GlobeNewswire February 5, 2024

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

GlobeNewswire January 25, 2024

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

GlobeNewswire December 9, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 10, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 9, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 8, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 7, 2023

FibroGen Reports Third Quarter 2023 Financial Results

GlobeNewswire November 6, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 3, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 2, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 1, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire October 31, 2023